EUCTR2013-001463-23-FR进行中（未招募）1 期
Randomized Phase II Study of Weekly ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer. - AFUGEM
GERCOR0 个研究点目标入组 114 人开始时间: 2013年9月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated informed consent, and willing and able to comply with protocol requirements,
- •2.Histologically or cytologically proven adenocarcinoma of the pancreas,
- •3.Metastatic disease confirmed (stage IV),
- •4.No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >12 months),
- •5.At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1 guidelines,
- •6.Age =18 years,
- •7.ECOG Performance status (PS) 0-2,
- •8.Hematological status: neutrophils (ANC) >1.5x109/L; platelets >100x109/L; haemoglobin =9g/dL,
- •9.Adequate renal function: serum creatinine level <150µM,
- •10.Adequate liver function: AST (SGOT) and ALT (SGPT) =2.5xULN (=5xULN in case of liver metastases)
- •11.Total bilirubin =1.5 x ULN, albumin =25g/L
- •12.Baseline evaluations performed before randomization: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization,
- •13.Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test (ß HCG) within 72 hours prior to starting ABI-007 treatment. Breastfeeding is not allowed. Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment,
- •14.Registration in a national health care system (CMU included for France).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 57
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 57
排除标准
- •1.History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy)
- •2.Local or locally advanced disease (stage I to III),
- •3.Patient uses warfarin,
- •4.Uncontrolled hypercalcemia,
- •5.Pre-existing permanent neuropathy (NCI grade =2),
- •6.Known dihydropyrimidine dehydrogenase (DPD) deficiency,
- •7.Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
- •8.Treatment with any other investigational medicinal product within 28 days prior to study entry,
- •9.Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months),
- •10.Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C.
- •11.History or active interstitial lung disease (ILD),
- •12.Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
- •13.Patients with known allergy to any excipient of study drugs,
- •14. Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine and concomitant administration of prophylactic phenytoin
研究者
相似试验
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic adenocarcinoma of the pancreasMedDRA version: 14.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ITABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO842
未知
1 期
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast CancerMetastatic breast cancerJPRN-jRCT2080221553Taiho Pharmaceutical Co., Ltd.24
进行中（未招募）
1 期
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ESAbraxis BioScience, LLC, an indirect subsidiary of Celgene Corporation842
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2009-011305-17-DEAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation842
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2009-011305-17-ATAbraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation842